패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

RVL Pharmaceuticals plc 10 애널리스트 중 0 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Louise Chen	Cantor Fitzgerald & Co.
David Steinberg	Jefferies LLC
Glen Santangelo	Jefferies LLC

RVL Pharmaceuticals 대차 대조표 상태

재무 상태 기준 확인 0/6

주요 정보

최근 재무 상태 업데이트

Nasdaq To File A Form 25-NSE with SEC Which Will Remove RVL Ordinary Shares from Listing and Registration on Nasdaq

RVL Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

RVL Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

RVL Pharmaceuticals (NASDAQ:RVLP) Is Making Moderate Use Of Debt

Is RVL Pharmaceuticals (NASDAQ:RVLP) Using Debt Sensibly?

RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of Debt

Recent updates

RVL Pharmaceuticals plc (OTCPK:RVLP.Q) offered to acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $11.5 million.

Nasdaq To File A Form 25-NSE with SEC Which Will Remove RVL Ordinary Shares from Listing and Registration on Nasdaq

RVL Pharmaceuticals plc Announces Resignation of Joaquin Benes and Juan Vergez from the Board of Directors

New major risk - Financial position

New minor risk - Profitability

Consensus revenue estimates fall by 26%

New major risk - Share price stability

Price target decreased by 15% to US$2.92

RVL Pharmaceuticals plc (NASDAQ:RVLP) Analysts Just Cut Their EPS Forecasts Substantially

New minor risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

RVL Pharmaceuticals plc to Report Q2, 2023 Results on Aug 14, 2023

RVL Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

RVL Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

No longer forecast to breakeven

Consensus revenue estimates decrease by 18%, EPS upgraded

Price target decreased by 7.3% to US$3.17

Analysts Just Made A Major Revision To Their RVL Pharmaceuticals plc (NASDAQ:RVLP) Revenue Forecasts

RVL Pharmaceuticals plc (NASDAQ:RVLP) Doing What It Can To Lift Shares

No longer forecast to breakeven

RVL Pharmaceuticals plc to Report Q1, 2023 Results on May 11, 2023

Price target decreased by 7.2% to US$3.42

RVL Pharmaceuticals (NASDAQ:RVLP) Is Making Moderate Use Of Debt

Consensus revenue estimates decrease by 14%, EPS upgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$3.42

Is RVL Pharmaceuticals (NASDAQ:RVLP) Using Debt Sensibly?

Forecast to breakeven in 2025

Third quarter 2022 earnings: EPS exceeds analyst expectations

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations

RVL Pharmaceuticals plc Reaffirms Sales Guidance for the Fourth Quarter of 2022

RVL Pharmaceuticals plc to Report Q3, 2022 Results on Nov 10, 2022

Insufficient new directors

Consensus revenue estimates fall by 14%

RVL Pharmaceuticals plc Revises Its Sales Guidance for the Fourth Quarter of 2022

RVL Pharmaceuticals sees Q3 net sales of UPNEEQ for eye treatment about $10M

RVL Pharmaceuticals: Chapter 2 - A Developing Quandary

RVL Pharma in pact with Revision Skincare to broaden access to products

No longer forecast to breakeven

Second quarter 2022 earnings: EPS exceeds analyst expectations

GAAP EPS of -$0.14 beats by $0.07, revenue of $8.45M misses by $0.07M

RVL Pharmaceuticals plc announced that it has received $23.949999 million in funding from Avista Capital Holdings, L.P., Athyrium Opportunities IV Co-Invest 2 LP

RVL Pharmaceuticals plc to Report Q2, 2022 Results on Aug 11, 2022

RVL Pharmaceuticals plc Reaffirms Sales Guidance for the Fourth Quarter of 2022

RVL Pharma posts preliminary 42% sales growth for eye treatment

RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of Debt

RVL Pharmaceuticals: Chapter 1 Gives A Mixed Picture

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

RVL Pharmaceuticals plc Reaffirms Sales Guidance for the Fourth Quarter of 2022

RVL Pharmaceuticals plc to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$5.20

RVL Pharmaceuticals plc, Annual General Meeting, Jun 16, 2022

Andrew Einhorn Resigns as Chief Financial Officer of RVL Pharmaceuticals, Effective April 18, 2022

RVL Pharmaceuticals plc Reaffirms Net Sales Guidance for the Fourth Quarter of 2022

Consensus revenue estimates increase by 12%

Price target decreased to US$5.20

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

New Forecasts: Here's What Analysts Think The Future Holds For RVL Pharmaceuticals plc (NASDAQ:RVLP)

RVL Pharmaceuticals plc Announces Impairment Charges for the Quarter Ended December 31, 2021

RVL Pharmaceuticals: A Makeover For An Ugly Duckling

Consensus forecasts updated

RVL Pharmaceuticals plc Provides Net Sales Guidance for the Fourth Quarter of 2022

Forecast to breakeven in 2024

Executive VP & COO recently bought US$100k worth of stock

Osmotica: A Different Breed Of Cat

Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.14 loss in 3Q 2020)

Price target decreased to US$6.50